公开(公告)号：US20240216495A1

公开(公告)日：2024-07-04

申请号：US18446883

申请日：2023-08-09

Applicant: Pfizer Inc.

Inventor： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Robert G.K. Donald ,  Michael James Flint ,  Nicholas Randolph Everard Kitchin ,  Justin Keith Moran ,  Louise Pedneault ,  Michael W. Pride ,  Mark Edward Ruppen ,  Christopher Frederick Webber

IPC: A61K39/08 ,  A61K9/19 ,  A61K39/00

CPC classification number: A61K39/08 ,  A61K9/19 ,  A61K2039/545

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, wherein the second administration is about 30 days after the first administration, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.

公开(公告)号：US20200254081A1

公开(公告)日：2020-08-13

申请号：US16647124

申请日：2018-09-14

Applicant: Pfizer Inc.

Inventor： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Robert G.K. Donald ,  Michael James Flint ,  Nicholas Randolph Everard Kitchin ,  Justin Keith Moran ,  Louise Pedneault ,  Michael W. Pride ,  Mark Edward Ruppen ,  Christopher Frederick Webber

IPC: A61K39/08 ,  A61K9/19

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, wherein the second administration is about 30 days after the first administration, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.

公开(公告)号：US20230218735A1

公开(公告)日：2023-07-13

申请号：US18001953

申请日：2021-06-17

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Alexey Vyacheslavovitch Gribenko ,  William Carl Gruber ,  Kathrin Ute Jansen ,  Lakshmi Khandke ,  Nicholas Randolph Everard Kitchin ,  Jody Lawrence ,  Yahong Peng ,  Michael William Pride ,  Christopher Frederick Webber ,  Sabine Susanne Wellnitz ,  Zhuobiao Yi

IPC: A61K39/08 ,  A61K47/26 ,  A61K9/19 ,  C07K16/12 ,  A61P31/04

CPC classification number: A61K39/08 ,  A61K47/26 ,  A61K9/19 ,  C07K16/1282 ,  A61P31/04 ,  A61K2039/55577

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.

公开(公告)号：US20220160859A1

公开(公告)日：2022-05-26

申请号：US17594107

申请日：2020-03-30

Applicant: Pfizer Inc.

Inventor： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Alexey Vyacheslavovitch Gribenko ,  Nicholas Randolph Everard Kitchin ,  Paul Liberator ,  Michael William Pride ,  Christopher Frederick Webber

IPC: A61K39/08 ,  A61P31/04 ,  C07K14/33 ,  C07K16/12

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.